Rakuten Takes Photoimmunotherapy Into Global Phase III Program For Head/Neck Cancer

 
• By Lisa Takagi

Oncology-focused venture eyes potential US approval for first-line use as it kicks off expanded development of light-activated therapy.

Rakuten head and neck cancer p3
Rakuten aims to enrol more than 400 patients in its global P3. (Shutterstock)

More from Clinical Trials

More from Business